Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Laceration of Skin, Anxiety, Discharge Time
Interventions
Intranasal Midazolam, Intranasal Dexmedetomidine, Intranasal Ketamine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 5 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Effect of Rapastinel on Driving Performance

NCT03814733
Conditions
Driving Performance
Interventions
Rapastinel, Alprazolam, Ketamine, Rapastinel Matched Placebo, Alprazolam Matched Placebo, Ketamine Matched Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
21 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Clemente, California
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Conditions
Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome
Interventions
Ketamine, Placebo saline
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
52
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 31 more
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Rapastinel in Humans

NCT03799900
Conditions
Human Abuse Potential
Interventions
Rapastinel, Ketamine, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Imaging SV2A in Mood Disorders

NCT02734602
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder
Interventions
Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1Phase 2 Interventional Results available

Intranasal (NAS) Ketamine for Cancer Pain

NCT03146806
Conditions
Cancer, Pain
Interventions
Intranasal ketamine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
Ketamine, Placebo/Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
Terminated Phase 4 Interventional Results available

Effect of Ketamine on Postoperative Clinical Outcomes

NCT01365195
Conditions
Colorectal Surgery
Interventions
Placebo, Ketamine high-dose, Ketamine low-dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Demoralization
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
Charles S. Grob, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Terminated Phase 4 Interventional Results available

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725
Conditions
Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions
Neuromuscular Blocking Agents, Anesthetic Adjuncts
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Depression, Anhedonia
Interventions
Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
Device · Behavioral · Drug
Lead sponsor
Erika Forbes
Other
Eligibility
15 Years to 25 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
MIJ821, Placebo, Ketamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more